Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two simple calculations could tell cancer from TB in fluid around the lungs

NCT ID NCT07766876

Diagnosis Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study looks at whether two simple calculations, called Cancer Ratio and Cancer Ratio Plus, can help doctors tell the difference between fluid around the lungs caused by cancer and fluid caused by tuberculosis. These calculations use results from routine blood and fluid tests. The study will include 120 adults with either malignant or tuberculous pleural effusion. Researchers will check how accurate these calculations are compared to standard diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cancer Ratio and Cancer Ratio Plus (diagnostic calculations using serum LDH, pleural fluid ADA, and lymphocyte percentage)
What this could lead to
If these simple calculations prove accurate, they could offer a faster, cheaper, and less invasive way to tell malignant from tuberculous pleural effusion, potentially reducing the need for more invasive biopsies.
What could go wrong
This is a single-center observational study, so results may not apply broadly. The markers' accuracy is still unproven, and they may not clearly distinguish all cases, especially in mixed or atypical presentations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include patients presenting with malignant or tuberculous pleural effusions who are admitted to the Chest Diseases Department of Sohag University hospital

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (≥18 years) * Patients with Malignant or tuberculous pleural effusion * Availability of complete pleural fluid analysis including lymphocyte percentage ,pleural fluid ADA, and Serum LDH level Exclusion Criteria: * Patients with mixed etiology effusions (e.g., malignancy with infection) * Prior pleural interventions affecting fluid analysis * Incomplete clinical or laboratory data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant pleural effusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pleural Effusion, Malignant pleural tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant pleural effusion Tuberculous pleural effusion

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.